Key highlights
- Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria at 37 weeks compared to placebo
- Primary endpoint met with high statistical significance (P<0.0001) in the IMAgINATION study
- Trial data showed consistent treatment effects across all prespecified patient subgroups
- A greater proportion of patients achieved hematuria resolution at Week 37 compared to placebo
- Study will continue for two years to evaluate long-term kidney function via eGFR at week 105
What Happened
Ionis Pharmaceuticals and Roche disclosed results from the ongoing Phase 3 IMAgINATION study evaluating sefaxersen in adults with primary IgA nephropathy. The trial reached its primary endpoint, showing a statistically significant 43.1% reduction in proteinuria compared to placebo at week 37. This metric was measured via the 24-hour urine protein-to-creatinine ratio, a critical marker for kidney damage. Additionally, patients with baseline hematuria showed improved resolution rates when treated with the investigational therapy. Sefaxersen is a once-monthly subcutaneous injection designed for self-administration, inhibiting complement factor B to reduce kidney inflammation and slow disease progression.
Significance
The IMAgINATION study will continue as a blinded trial for two years to assess long-term changes in kidney function, specifically evaluating the estimated glomerular filtration rate at week 105. Under the existing licensing agreement, Ionis received an upfront payment and remains eligible for future regulatory and sales milestones, plus tiered royalties on net sales. Roche intends to share these data with global health authorities to accelerate the path toward commercialization. Successful development addresses a significant unmet need in Berger disease, an autoimmune condition that leads to end-stage kidney failure in approximately 50% of patients within two decades.
Business Overview
- Specializes in RNA-targeted therapeutics using proprietary antisense technology
- Diverse pipeline covering cardiovascular, metabolic, and neurological diseases
- Recent FDA approval of Zanvastro for the treatment of Alexander disease
- FDA approval of partner GSK Hibsago for chronic hepatitis B in October 2026
- Positive Phase 3 results for ulefnersen in FUS-ALS neurological studies
- Strategic partnerships with industry leaders including Roche, GSK, and Novartis
Financial Context
Ionis currently holds a market capitalization of approximately $7.12 billion, with trailing twelve-month revenues totaling $943.7 million. For the 2026 fiscal year, management has reaffirmed revenue guidance between $875 million and $900 million. While the company stock performance reflects a quarterly decline of 20.68%, technical indicators show an RSI of 39.6. The company capital structure is reinforced by upfront payments and tiered royalties from established partners. Financial results for the third quarter of 2026 are scheduled for release on November 4, 2026, which may provide further updates on the broader commercial pipeline.
Down 34.6% since our story on 23 Oct: $42.84 when we broke it → $28.01 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $44.38 |
|---|---|
| 20 Oct | $45.40 |
| 21 Oct | $44.27 |
| 22 Oct | $43.91 |
| 23 Oct | $42.93 |
| 26 Oct | $43.42 |
| 27 Oct | $43.96 |
| 28 Oct | $44.90 |
| 29 Oct | $44.39 |
| 30 Oct | $43.52 |
| 2 Nov | $41.24 |
| 3 Nov | $40.42 |
| 4 Nov | $40.15 |
| 5 Nov | $38.80 |
| 6 Nov | $39.42 |
| 9 Nov | $31.00 |
| 10 Nov | $28.19 |
| 11 Nov | $28.33 |
| 12 Nov | $27.31 |
| 13 Nov | $29.06 |
| 16 Nov | $28.01 |
Industry Landscape
IgA nephropathy is the most common form of primary glomerulonephritis, affecting at least 25 adults per million worldwide annually. The therapeutic landscape for chronic kidney disease is shifting toward targeted RNA-based interventions that address underlying complement-mediated inflammation. While the industry recently saw a Phase 3 miss for pelacarsen in cardiovascular applications by partner Novartis, the nephrology sector remains a high-growth area due to the high costs associated with long-term dialysis and transplantation. Competitors and partners alike are focusing on subcutaneous delivery systems that enhance patient adherence by allowing at-home administration for chronic autoimmune conditions.
| Date | Announcement | Amount |
|---|---|---|
| 20 Oct 2026 | FDA approval of partner GSK's HIBSAGO (bepirovirsen) for chronic hepatitis BSource: SEC filing | – |
| 16 Oct 2026 | European CHMP positive opinion recommending approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemiaSource: ir.ionis.com | – |
| 23 Sep 2026 | Positive Phase 3 IMAgINATION interim trial results with partner Roche for sefaxersen in IgA nephropathySource: SEC filing | – |
| 22 Sep 2026 | Positive topline results from Phase 3 FUSION study of ulefnersen in FUS-ALSSource: ir.ionis.com | – |
| 04 Sep 2026 | Partner Novartis reported pelacarsen Phase 3 Lp(a)HORIZON study missed primary endpointSource: SEC filing | – |
| 03 Sep 2026 | FDA approval of ZANVASTRO (zilganersen) for Alexander diseaseSource: SEC filing | – |
Management commentary
“These data support our belief that sefaxersen is uniquely positioned to treat IgA nephropathy, demonstrating significant and clinically meaningful reduction in proteinuria and offering the potential to help reduce the need for long-term dialysis or kidney transplantation.”
| Share price | $42.84 |
|---|---|
| Market cap | $7.1B |
| Revenue (annual) | $944M |
| 1-month price change | -2.48% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Ionis Pharmaceuticals, Inc. announcing Phase 3 IMAgINATION study results for sefaxersen.
Track IONIS PHARMACEUTICALS INC live
Get the next IONIS PHARMACEUTICALS INC SEC filing seconds after it lands.




